The Green Room: Virtual Nature for Mental Well-being in the Acute Psychiatry Ward
GREEN ROOM
The Green Room: A Mixed-Methods Randomized Controlled Trial Evaluating Virtual Reality-Based Nature Exposure in an Acute Psychiatry Ward
1 other identifier
interventional
120
1 country
1
Brief Summary
This study evaluates the feasibility, acceptability and clinical impact of a virtual reality (VR)- based nature intervention in an acute psychiatric inpatient unit. Participants are randomly assigned to recieve VR nature sessions (using Nature Treks VR on Meta Quest 3) in addition to standard care, or standard care alone. The primary outcome is change in percieved stress (PSS-19) from admission to discharge. The study uses a mixed-methods design combining randomized controlled trial with a qualitative phase.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 9, 2026
CompletedStudy Start
First participant enrolled
June 10, 2026
CompletedFirst Posted
Study publicly available on registry
June 17, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
June 17, 2026
June 1, 2025
6 months
June 9, 2026
June 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Perceived Stress Scale-10 (PSS-10) score
Change in PSS-10 total score from baseline assessment (T0, al clinical stabilization) to discharge assessment (T2). The Perceived Stress Scale-10 (PSS-10) is a 10-item self-report questionnaire measuring the degree to which situations in one's life are appraised as stressful. Scores range from 0 to 40, with higher scores indicating greater perceived stress.
From admission (baseline) to discharge (average 2-3 weeks)
Secondary Outcomes (10)
World Health Organization-Five Well-Being Index (WHO-5) score
Through study completion, an average of 2 weeks
Views On Inpatient Care (VOICE) score
Through study completion, an average of 2 weeks
Client's Assessment of Treatment (CAT) score
Through study completion, an average of 2 weeks
Length of hospital stay
From admission to discharge, an average of 2 weeks
Rate of discharge against medical advice (DAMA)
Throughout hospitalization, an average 2 weeks.
- +5 more secondary outcomes
Study Arms (2)
VR + Treatment as Usual
EXPERIMENTALParticipants receive voluntary VR nature sessions (10-15 minutes, every other day) using Meta Quest 3, in addition to standar psychiatric care.
Treatment as Usual (TAU)
ACTIVE COMPARATORParticipantrs receive standard pharmacological and psychotherapeutic care provided by the acute psychiatry ward, without VR sessions.
Interventions
Voluntary immersive nature sessions using Nature Treks VR softwere on Meta Quest 3 head-mounted displays. Sessions last 10-15 minutes and are offered every other day throughout hospitalization. Participants freely choose among all available nature environments within the application.
Standard pharmacological and psychotherapeutic interventions provided by the acute psychiatry ward.
Eligibility Criteria
You may qualify if:
- Adults aged 18 to 65 years. Admitted to the Acute Psychiatry Ward (regardless of voluntary or involuntary legal status).
- Sufficient cognitive and clinical stability to provide informed consent and engage with the VR equipment, as determined by the clinical team.
- Ability to communicate effectively in Spanish.
You may not qualify if:
- History of photosensitive epilepsy or severe seizure disorders. Presence of active facial injuries, infections, or skin conditions that prevent the hygienic use of the VR headset.
- Pre-existing severe vertigo, balance disorders, or high susceptibility to motion sickness.
- Acute clinical state involving high risk of agitation or behavioral dysregulation that could compromise participant or equipment safety.
- Severe visual or hearing impairments that cannot be corrected and would hinder the VR experience.
- Patients who have previously participated in the study during a prior admission are not eligible for re-enrolment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Clinic de Barcelona
Barcelona, Barcelona, Spain
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pablo Barrio Gimenez
Hospital Clinic of Barcelona
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 9, 2026
First Posted
June 17, 2026
Study Start
June 10, 2026
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
June 17, 2026
Record last verified: 2025-06